Human Pluripotent Stem Cells (hPSCs) are particularly prone to developing abnormalities during their time in culture. In 5 passages or less, the variants that appear can rapidly become predominant, compromising your research work.
Traditional G-Banding karyotyping is helpful in providing an exhaustive structural and numerical variant analysis. However, it does not have the required sensitivity to identify the most frequent genomic defects in human pluripotent stem cells.
Additionally, hPSC research scientists need assays designed for in-process testing every 5-10 passages (Assou et al., 2020; McIntire et al., 2020; Pamies et al., 2017) in order to pick up abnormalities as early as possible in their workflow, and G-Banding is not designed to support that level of frequency in testing.
The sensitivity and speed required in delivering a reliable assessment of genomic stability in hPSCs led Stem Genomics to develop the iCS-digital™ PSC range.
Thanks to the high level of performance offered by digital PCR (200 bp and 20% mosaicism) combined with an in-depth analysis of most recurrent abnormalities in hPSCs (see SMART database), the iCS-digital™ PSC range of tests can detect sub-karyotyping abnormalities that G-Banding would miss.
Human PSCs:
ESCs & iPSCs
In-process control during cell amplification & maintenance
Clone screening
Banking characterization
gDNA
Cell pellet
Room temperature
Dry ice
Test with 28 probes: 93% of recurrent abnormalities
Test with 24 probes: 90% of recurrent abnormalities
Test the 20q11.21 region: the most common genomic abnormality in hPSCs (>20%)
2-3 days after sample reception
Available as a service
(from one sample) or a kit:
Recommended guidelines in terms of genomic stability advise checking the cells every 5-10 passages during their time in culture, but also screening clones after any stressing process (reprogramming, gene editing, etc.) and during banking. It is also advisable when a new line is acquired.
Click on the graph for more details:
If your raw material is not stable, it is difficult to trust any differentiation changes down the line. Therefore, whilst we are verifying your cell line pluripotency, why not also check for potential genomic abnormalities or mycoplasma at the same time? We have fast and high-performing digital PCR tests that will enable you to perform these tests simultaneously. This will also enable you to benefit from additional discounts.
New: you can now order up to 5 tests designed specifically for pluripotent stem cell workflows in one go.
Watch a quick video presentation of the one-stop-shop service
In order to accurately target the abnormalities relevant for hPSC researchers, Stem Genomics specifically analysed the data from 132 scientific publications concerning 1485 hPSC samples. After exclusion of polymorphic variants, we highlighted the presence of 949 recurrent genetic abnormalities (i.e., genomic defects found in at least five different publications).
We then used these data to develop the iCS-digital™ PSC test.
We are quick to respond
Let's talk to each other
According to your availability
Subscribe to stay informed
Cap Sigma
1682 rue de la Valsière
34 790 Grabels
400 Park Offices Drive
Room 105
Research Triangle Park
Durham, NC 27713
As of July 17, our new address will be:
400 Park Offices Drive, Room 105
Research Triangle Park, Durham, North Carolina 27713
Please note that we will be closed from July 12 to 16
during the transition.
Please enter your details below
Please enter your details below
Join us LIVE for a Q&A session on the latest iCS-digital™ PSC upgrade.
Find out what it means for you and ask all your questions
Juline VINCENT our R&D Project Manager and Digital PCR expert will answer you LIVE.
SAVE THE DATE: Thursday, November 7, 6pm CET/9am PDT/12 pm EDT.
Join us LIVE for our webinar!
Best Practices: Making your hPSC Quality Control workflow more efficient
Join Juline VINCENT, our R&D Project Manager, as she presents efficient quality control strategies specifically designed to address the unique characteristics of pluripotent stem cells.
Thursday, October 23, 12:00 PM EST / 6:00 PM CET
Please enter your e-mail address.
